Help me prepare questions for GDM,APH,PPH,PROM,PPROM,preterm labour,FGR,Abnormal presentation,obstetrics emergencies

Reading File

I'll first extract the PDF to understand the question format, then search the medical library for all topics simultaneously.

Running Command

python3 -c " import pdfplumber with pdfplumber.open('/tmp/workspace/attachments/803a05a8-8b14-4654-a3e1-2790cc244b67/Eop MEQ_260612_112714.pdf') as pdf: print(f'Total pages: {len(pdf.pages)}') for i, page in enumerate(pdf.pages): text = page.extract_text() if text: print(f'--- PAGE {i+1} ---') print(text[:3000]) "

Finding Sources

Running Command

python3 -c " import pdfplumber with pdfplumber.open('/tmp/workspace/attachments/803a05a8-8b14-4654-a3e1-2790cc244b67/Eop MEQ_260612_112714.pdf') as pdf: for i, page in enumerate(pdf.pages): text = page.extract_text() if text: print(f'--- PAGE {i+1} ---') print(text) "

Finding Sources

analyse_media

Finding Sources

Running Command

python3 << 'EOF' import pdfplumber pdf_path = '/tmp/workspace/attachments/803a05a8-8b14-4654-a3e1-2790cc244b67/Eop MEQ_260612_112714.pdf' with pdfplumber.open(pdf_path) as pdf: print(f"Total pages: {len(pdf.pages)}") for i, page in enumerate(pdf.pages): print(f"\n===== PAGE {i+1} =====") # Try extracting words words = page.extract_words() print(f"Words count: {len(words)}") # Try text with different settings text = page.extract_text(x_tolerance=3, y_tolerance=3) if text: print("TEXT:") print(text) else: print("No text extracted") # Try getting all text objects chars = page.chars print(f"Chars count: {len(chars)}") if chars: # Reconstruct text from chars text2 = ''.join([c['text'] for c in chars]) print("CHARS TEXT (first 2000):") print(text2[:2000]) EOF

The PDF appears to be a scanned image-based file (no extractable text). Let me convert it to images and analyze the content.

Running Command

python3 << 'EOF' from pypdf import PdfReader import base64 pdf_path = '/tmp/workspace/attachments/803a05a8-8b14-4654-a3e1-2790cc244b67/Eop MEQ_260612_112714.pdf' reader = PdfReader(pdf_path) print(f"Pages: {len(reader.pages)}") print(f"Metadata: {reader.metadata}") # Check if there are images embedded for i, page in enumerate(reader.pages): print(f"\nPage {i+1}:") print(f" Resources: {list(page.get('/Resources', {}).keys()) if page.get('/Resources') else 'None'}") resources = page.get('/Resources') if resources: xobj = resources.get('/XObject') if xobj: print(f" XObjects: {list(xobj.keys())}") for key in xobj.keys(): obj = xobj[key] print(f" {key}: subtype={obj.get('/Subtype')}, width={obj.get('/Width')}, height={obj.get('/Height')}") EOF

Running Command

python3 << 'EOF' # Try to render PDF pages as images using PIL/Pillow with pdf2image or pypdfium2 import subprocess result = subprocess.run(['pip', 'show', 'pypdfium2'], capture_output=True, text=True) print("pypdfium2:", result.stdout[:200] if result.stdout else "not found") result2 = subprocess.run(['pip', 'show', 'pdf2image'], capture_output=True, text=True) print("pdf2image:", result2.stdout[:200] if result2.stdout else "not found") result3 = subprocess.run(['pip', 'show', 'pymupdf'], capture_output=True, text=True) print("pymupdf:", result3.stdout[:200] if result3.stdout else "not found") result4 = subprocess.run(['pip', 'show', 'fitz'], capture_output=True, text=True) print("fitz:", result4.stdout[:200] if result4.stdout else "not found") EOF

Running Command

python3 << 'EOF' import pypdfium2 as pdfium from PIL import Image import os os.makedirs('/tmp/workspace/pdf_pages', exist_ok=True) pdf_path = '/tmp/workspace/attachments/803a05a8-8b14-4654-a3e1-2790cc244b67/Eop MEQ_260612_112714.pdf' pdf = pdfium.PdfDocument(pdf_path) print(f"Pages: {len(pdf)}") for i in range(len(pdf)): page = pdf[i] bitmap = page.render(scale=2) # 2x scale for better quality pil_image = bitmap.to_pil() out_path = f'/tmp/workspace/pdf_pages/page_{i+1}.png' pil_image.save(out_path) print(f"Saved page {i+1}: {pil_image.size}") pdf.close() print("Done!") EOF

Reading File

analyse_media

The PDF is a scanned document. The analyse_media tool needs an HTTP URL. Let me try a different approach to read the image content directly.

Running Command

python3 << 'EOF' # Try OCR-like text extraction using pypdfium2's text page import pypdfium2 as pdfium pdf_path = '/tmp/workspace/attachments/803a05a8-8b14-4654-a3e1-2790cc244b67/Eop MEQ_260612_112714.pdf' pdf = pdfium.PdfDocument(pdf_path) for i in range(len(pdf)): page = pdf[i] textpage = page.get_textpage() text = textpage.get_text_range() print(f"\n===== PAGE {i+1} =====") print(repr(text[:500]) if text else "NO TEXT") print(text[:2000] if text else "") pdf.close() EOF

The PDF is fully scanned with no text layer. I cannot read the content from it directly. I'll now proceed to generate a comprehensive set of MEQ-style questions for all the requested topics based on my clinical knowledge and the medical library.

Finding Sources

I now have enough context. The PDF is a scanned file with no extractable text - I'll note it uses an MEQ (Modified Essay Question) format based on its name. Let me now compose a comprehensive, high-quality MEQ question bank for all 9 topics.> Note on the PDF: The uploaded file is a scanned image PDF with no text layer, so its content could not be extracted. However, based on its filename ("Eop MEQ") it is an MEQ (Modified Essay Question) exam paper. The questions below follow the standard MEQ clinical vignette format used in such exams.

Obstetrics MEQ Question Bank

1. GESTATIONAL DIABETES MELLITUS (GDM)

MEQ 1 — GDM Screening & Diagnosis

A 29-year-old woman (G2P1) at 26 weeks gestation attends her antenatal clinic. Her BMI is 32 kg/m², she has a family history of type 2 diabetes, and her previous baby weighed 4.2 kg. Her random blood glucose today is 7.8 mmol/L.

a) List FOUR risk factors for GDM present in this woman. (2 marks)

b) What is the recommended screening test for GDM, and what are the diagnostic thresholds using the WHO 2013 / IADPSG criteria for the 75 g OGTT? (3 marks)

c) Her 75 g OGTT results: Fasting 5.4 mmol/L, 1-hour 10.8 mmol/L, 2-hour 9.1 mmol/L. Does she have GDM? Justify. (2 marks)

d) Outline the initial management of her GDM. (3 marks)

Model Answers:

(a) BMI >30, family history of T2DM, previous macrosomic baby (>4 kg), previous GDM (implied by parity) - any 4 from: obesity, family history, macrosomia, ethnicity, age >35, PCOS, polyhydramnios
(b) 75 g OGTT at 24-28 weeks. Diagnostic if ANY value is met or exceeded: Fasting ≥5.1 mmol/L; 1-hour ≥10.0 mmol/L; 2-hour ≥8.5 mmol/L
(c) YES - GDM confirmed. 1-hour value 10.8 ≥ 10.0 mmol/L and 2-hour 9.1 ≥ 8.5 mmol/L (both thresholds met, only one needed)
(d) Medical nutrition therapy (carbohydrate-controlled diet), structured exercise, blood glucose self-monitoring (fasting + 1-2h postprandial targets), fetal surveillance with growth scans, if targets not met after 1-2 weeks initiate metformin or insulin

MEQ 2 — GDM Complications & Intrapartum Management

A woman with well-controlled GDM on insulin (Mixtard 30) reaches 38 weeks gestation. USS shows estimated fetal weight of 4.0 kg. She asks about delivery.

a) What are the maternal complications of uncontrolled GDM? (3 marks)

b) What fetal/neonatal complications are associated with GDM? (4 marks)

c) What are the glycaemic targets during labour? How is insulin managed intrapartum? (3 marks)

d) What postnatal follow-up is required for this woman? (2 marks)

Model Answers:

(a) Preeclampsia, polyhydramnios, operative delivery (CS/instrumental), UTI, worsening retinopathy/nephropathy if pre-existing DM
(b) Macrosomia/shoulder dystocia, neonatal hypoglycaemia, respiratory distress syndrome, polycythaemia, hyperbilirubinaemia, stillbirth, birth trauma (clavicle fracture, brachial plexus injury)
(c) Target capillary glucose 4-7 mmol/L during labour. Use glucose-insulin-potassium (GIK) infusion OR variable-rate insulin infusion (VRIII); stop long-acting insulin; check glucose 1-hourly
(d) 75 g OGTT at 6-13 weeks postpartum to screen for T2DM; annual HbA1c/fasting glucose; lifestyle counselling; pre-conception counselling for future pregnancies

2. ANTEPARTUM HAEMORRHAGE (APH)

MEQ 3 — Placenta Praevia

A 32-year-old woman (G3P2, one previous CS) presents at 32 weeks gestation with a sudden onset of painless, fresh, bright-red vaginal bleeding. She is haemodynamically stable. USS is available.

a) Define APH. What is the likely diagnosis here, and what features in the history support it? (3 marks)

b) Classify placenta praevia (Grades I-IV or RCOG classification). (2 marks)

c) How would you investigate this woman? (3 marks)

d) Outline the management if she remains haemodynamically stable. (4 marks)

e) Why is vaginal examination CONTRAINDICATED in this woman before USS? (1 mark)

Model Answers:

(a) APH = bleeding from the genital tract after 24 weeks gestation and before delivery. Likely: Placenta praevia. Features: painless, fresh, bright red, no preceding trauma; previous CS (risk factor for low-lying placenta/accreta)
(b) Grade I: placenta in lower segment, does not reach os; Grade II: reaches internal os; Grade III: partially covers os; Grade IV: completely covers os (major praevia). RCOG: Minor (I, II anterior) vs Major (II posterior, III, IV)
(c) FBC (Hb, platelets), coagulation screen, blood group & cross-match (4 units), USS with transvaginal probe for placental localisation, Kleihauer-Betke if Rhesus-negative, CTG
(d) Admit, IV access x2, IV fluids, oxygen, blood transfusion if needed; corticosteroids (betamethasone 12 mg IM x2, 24h apart) for lung maturity at 32 weeks; Anti-D prophylaxis if Rh-negative; if bleeding settles, conservative management until 36-37 weeks; plan elective CS; avoid vaginal examination; weekly USS and CTG surveillance
(e) Digital VE could provoke massive haemorrhage by disturbing the overlying placenta ("forbidden examination")

MEQ 4 — Placental Abruption

A 28-year-old (G2P1) at 35 weeks presents with sudden onset severe, constant abdominal pain and dark red vaginal bleeding after a road traffic accident. On examination the uterus is "woody hard" and tender. FHR is 90 bpm on CTG.

a) What is the diagnosis? Name FOUR predisposing factors. (3 marks)

b) Define "concealed" vs "revealed" abruption. (2 marks)

c) The CTG shows a prolonged deceleration. What is your immediate management? (4 marks)

d) What coagulation complication may arise and how would you manage it? (3 marks)

Model Answers:

(a) Placental abruption. Risk factors: trauma/RTA, hypertension/preeclampsia, smoking, cocaine use, previous abruption, thrombophilia, PROM, polyhydramnios (sudden decompression), multiple pregnancy
(b) Revealed: blood tracks between membranes and escapes through cervix (visible); Concealed: blood accumulates behind placenta, uterus expands, no visible bleeding (underestimates blood loss)
(c) Call for help - emergency crash team/obstetric emergency bell; airway/breathing/circulation - 2 x large-bore IV, aggressive fluid resuscitation, blood products; urgent CS (category 1) given fetal bradycardia; blood group & cross-match 6 units, coagulation screen, FBC; neonatology team standby; ongoing CTG
(d) Disseminated intravascular coagulation (DIC) - due to release of thromboplastin from damaged placenta. Manage: fresh frozen plasma (FFP) 15 ml/kg, cryoprecipitate for fibrinogen <1.5 g/L, platelet transfusion if <50 x10⁹/L, red cell transfusion, haematology involvement, target fibrinogen >2 g/L

3. POSTPARTUM HAEMORRHAGE (PPH)

MEQ 5 — Primary PPH

A 26-year-old primigravida undergoes normal vaginal delivery at term. Active management of the third stage was given. She delivers the placenta at 10 minutes but continues to bleed. You estimate blood loss of 750 ml and it is continuing. The uterus feels "boggy" on palpation.

a) Define primary PPH and classify its severity. (2 marks)

b) What are the "4 T's" of PPH? Which is the most common cause? (3 marks)

c) Outline the stepwise management of this woman. (5 marks)

d) Name the uterotonic agents used in managing PPH, including doses. (3 marks)

Model Answers:

(a) Primary PPH: blood loss ≥500 ml within 24 hours of delivery. Minor: 500-1000 ml; Major: >1000 ml (subdivided moderate 1000-2000 ml, severe >2000 ml)
(b) Tone (70% - uterine atony, most common), Trauma (lacerations, uterine rupture), Tissue (retained placenta/membranes), Thrombin (coagulopathy)
(c) Call for help (senior obstetrician, anaesthetist, midwife, haematologist); ABC - 2 large-bore IV access, FBC, coagulation, cross-match 4 units; IV crystalloid/colloid; catheterise bladder (full bladder prevents uterine contraction); bimanual uterine compression/massage; uterotonic drugs (oxytocin, ergometrine, carboprost, misoprostol); if bleeding continues → examine under anaesthesia for trauma/retained products; intrauterine balloon tamponade (Bakri balloon); surgical: B-Lynch compression suture, uterine artery ligation, internal iliac artery ligation; hysterectomy as last resort; interventional radiology (uterine artery embolisation) if available
(d) Oxytocin (Syntocinon) 10 IU IV slow bolus or 40 IU in 500 ml N/saline infusion; Ergometrine 0.5 mg IM/IV (avoid in hypertension); Syntometrine (oxytocin 5 IU + ergometrine 0.5 mg) IM; Carboprost (15-methyl PGF2α) 0.25 mg IM every 15 min up to 8 doses (avoid in asthma); Misoprostol 800-1000 mcg sublingual/rectal/oral; Tranexamic acid 1 g IV (within 3 hours)

MEQ 6 — Secondary PPH & Risk Factors

A 34-year-old woman (G3P3) who had a normal vaginal delivery 12 days ago presents with heavy, offensive vaginal bleeding and fever.

a) Define secondary PPH. What are the causes? (3 marks)

b) List SIX antenatal risk factors for PPH. (3 marks)

c) How would you manage this woman? (4 marks)

Model Answers:

(a) Secondary PPH: abnormal or excessive bleeding from birth canal between 24 hours and 12 weeks postpartum. Causes: retained products of conception (most common), endometritis/infection, subinvolution of placental site, inherited coagulopathy (e.g., vWD)
(b) Previous PPH, placenta praevia/accreta, multiple pregnancy, polyhydramnios, macrosomia, grande multiparity, fibroids, coagulopathy, antepartum haemorrhage, prolonged labour, pre-eclampsia, anaemia
(c) Admit; IV access, FBC, CRP, blood cultures, endocervical swabs, pelvic USS (to identify retained products); IV antibiotics (broad spectrum - e.g., co-amoxiclav + metronidazole); if USS confirms retained products → surgical evacuation of uterus (ERPC) under anaesthesia; Anti-D if Rh-negative; supportive care (iron supplementation)

4. PREMATURE RUPTURE OF MEMBRANES (PROM) - at term (≥37 weeks)

MEQ 7 — PROM at Term

A 38-year-old (G1P0) at 38+4 weeks presents with a sudden gush of clear fluid from the vagina 8 hours ago. She has no contractions. Temperature 36.8°C, FHR 142 bpm, no uterine tenderness.

a) How would you confirm the diagnosis of PROM? (3 marks)

b) What are the risks of expectant management vs induction of labour in PROM at term? (3 marks)

c) What is the recommended management according to NICE guidelines? (2 marks)

d) What are the clinical signs of chorioamnionitis? (3 marks)

Model Answers:

(a) History (history of gush is highly diagnostic); Speculum examination: pooling of amniotic fluid in posterior fornix, ferning on microscopy, fluid seen coming from os; IGFBP-1/AFP dipstick test (AmniSure/Actim PROM); USS - oligohydramnios; avoid digital VE (increases infection risk)
(b) Expectant: 60% go into labour within 24h, 95% within 72h; risk of chorioamnionitis increases with time (2-3% at 24h, rises thereafter); risk of cord prolapse (if presenting part not engaged). Induction: reduces infection risk; higher oxytocin use; may increase CS risk (if not ready)
(c) NICE: Offer induction of labour after 24 hours if not in labour (or earlier if risk factors present: GBS positive, previous GBS baby, pyrexia, offensive discharge). Expectant management for 24 hours acceptable if no risk factors and woman prefers
(d) Maternal pyrexia >38°C, maternal tachycardia >100 bpm, fetal tachycardia >160 bpm, uterine tenderness, offensive/purulent liquor, raised WCC, raised CRP; formal diagnosis requires 2+ criteria

5. PRETERM PREMATURE RUPTURE OF MEMBRANES (PPROM)

MEQ 8 — PPROM

A 24-year-old (G1P0) at 28 weeks presents with a gush of fluid. Speculum confirms pooling of liquor. She is afebrile, CTG is reactive, no contractions.

a) What is PPROM? What are its causes/associations? (3 marks)

b) What investigations would you perform? (3 marks)

c) What is the role of antibiotics in PPROM? Which antibiotic is preferred and why is co-amoxiclav AVOIDED as first line? (3 marks)

d) Outline the management plan for this woman at 28 weeks. (4 marks)

Model Answers:

(a) PPROM = rupture of fetal membranes before 37 weeks gestation, prior to onset of labour. Causes: ascending infection (most common), cervical incompetence, polyhydramnios, multiple pregnancy, uterine abnormalities, amniocentesis, smoking, previous PPROM, STIs, bacterial vaginosis, antepartum haemorrhage
(b) FBC, CRP, blood cultures (if febrile), high vaginal swab (HVS), low vaginal swab for GBS, MSU, USS for liquor volume and fetal biophysical profile, CTG, vaginal pH, IGFBP-1 test (AmniSure) to confirm, fibronectin
(c) Antibiotics reduce chorioamnionitis, neonatal infection, and delay delivery (prolongs pregnancy by ~1 week on average). Preferred: Erythromycin 250 mg QDS orally for 10 days (ORACLE I trial). Co-amoxiclav AVOIDED because the ORACLE I trial showed significantly increased risk of neonatal necrotising enterocolitis (NEC) when co-amoxiclav was used
(d) Admit to hospital with neonatal intensive care; corticosteroids (betamethasone 12 mg IM x2, 24h apart) for fetal lung maturity; erythromycin 250 mg QDS x10 days; consider magnesium sulphate for neuroprotection (if <30 weeks, per local protocol); daily monitoring: temperature, pulse, FBC, CRP, CTG; USS every 1-2 weeks (liquor, growth, biophysical profile); aim for expectant management to 34-37 weeks (balance infection vs prematurity); if signs of chorioamnionitis/fetal compromise - deliver

6. PRETERM LABOUR

MEQ 9 — Preterm Labour

A 30-year-old woman (G2P1, previous preterm birth at 32 weeks) presents at 29 weeks with regular painful contractions every 5 minutes. Speculum shows intact membranes. Cervical length by USS is 18 mm. Fetal fibronectin is positive.

a) Define preterm labour. What are its risk factors? (3 marks)

b) What is the role of fetal fibronectin and cervical length measurement? (3 marks)

c) What tocolytic agents can be used? Name ONE preferred agent and its contraindications. (4 marks)

d) What other interventions should be given at 29 weeks? (3 marks)

Model Answers:

(a) Preterm labour: regular uterine contractions causing cervical change before 37 completed weeks. Risk factors: previous preterm birth (strongest), multiple pregnancy, cervical incompetence/short cervix, PPROM, uterine abnormality (bicornuate uterus, fibroids), infection (BV, UTI), smoking, low BMI, extremes of age, polyhydramnios, placenta praevia, antepartum haemorrhage, PCOS, socioeconomic deprivation
(b) Cervical length <25 mm by transvaginal USS = increased risk of preterm birth; <15 mm = high risk. Fetal fibronectin (fFN): a glycoprotein found between chorion and decidua; if POSITIVE (>50 ng/mL) at 22-34 weeks = 7x increased risk of delivery within 7 days; if NEGATIVE = >95% chance she will NOT deliver within 7 days (high NPV - useful to avoid unnecessary treatment)
(c) Tocolytics: Nifedipine (calcium channel blocker - first line in many centres), Atosiban (oxytocin receptor antagonist - first line in UK/NICE), Indometacin (prostaglandin inhibitor, <32 weeks), Ritodrine/Salbutamol (beta2-agonists - older, less favoured). Preferred: Atosiban - bolus 6.75 mg IV then infusion. Contraindications of tocolytics (atosiban): <24 weeks or ≥34 weeks, intrauterine infection, fetal compromise, antepartum haemorrhage, placenta praevia with bleeding, lethal fetal anomaly
(d) Corticosteroids: betamethasone 12 mg IM x2, 24 hours apart (reduces RDS, IVH, NEC); Magnesium sulphate 4 g IV loading dose then 1 g/hour for neuroprotection (reduces cerebral palsy <32 weeks - MagNET/BEAM trials); in-utero transfer to unit with NICU; inform neonatal team; GBS prophylaxis (IV benzylpenicillin) in labour if GBS-positive or unknown

7. FETAL GROWTH RESTRICTION (FGR)

MEQ 10 — FGR

At a routine 32-week scan, a 35-year-old woman (G1P0) with chronic hypertension is found to have estimated fetal weight on the 3rd centile with absent end-diastolic flow (AEDF) on umbilical artery Doppler.

a) Define FGR. Distinguish between early-onset and late-onset FGR. (3 marks)

b) What are the causes of FGR? (4 marks)

c) Explain the significance of Doppler findings: (i) AEDF (ii) Reversed end-diastolic flow (REDF) (iii) Absent/reversed "a" wave in ductus venosus. (3 marks)

d) What is the management plan for this woman? When would you deliver? (4 marks)

Model Answers:

(a) FGR: failure of a fetus to reach its biologically determined growth potential. Operationally defined as AC/EFW <10th centile (some use <3rd centile for severe FGR). Early-onset: <32 weeks, often associated with severe placental dysfunction, abnormal Dopplers, worse prognosis. Late-onset: ≥32 weeks, subtler Doppler changes, accounts for majority but often missed
(b) Maternal: hypertension/preeclampsia, smoking, malnutrition, anaemia, antiphospholipid syndrome, thrombophilia, renal disease, SLE, substance abuse, low socioeconomic status. Placental: placenta praevia, abruption, multiple pregnancy, placental infarction. Fetal: chromosomal abnormalities (trisomy 18, 13), congenital infection (CMV, rubella, toxoplasma, syphilis), structural anomalies. Idiopathic (largest group)
(c) (i) AEDF: severe placental resistance; fetal hypoxia likely developing; close monitoring required, consider delivery if near term. (ii) REDF: critical placental compromise; imminent fetal acidosis; deliver promptly (usually within 24-48h). (iii) Absent/reversed "a" wave in ductus venosus: indicates fetal cardiac decompensation (right heart failure); deliver immediately
(d) Admit or very close monitoring; serial USS every 2 weeks for growth, weekly Doppler; daily or twice-daily CTG; aim to prolong pregnancy to ≥34 weeks if Dopplers stable (AEDF but not REDF); corticosteroids if <34 weeks; with AEDF at 32 weeks - admit, steroids, deliver at 34 weeks or sooner if deterioration (REDF, absent DV, decelerations on CTG, biophysical score ≤4). Delivery: CS likely given FGR with abnormal Dopplers; neonatology standby; magnesium sulphate if <32 weeks

8. ABNORMAL PRESENTATION

MEQ 11 — Breech Presentation

A 37-year-old (G2P1) is found on examination at 36 weeks to have a breech presentation confirmed on USS. The fetus is in extended (frank) breech position, EFW 2.9 kg, liquor normal, no placenta praevia.

a) What are the types of breech presentation? (2 marks)

b) What are the causes of persistent breech at term? (3 marks)

c) What options are available to this woman for delivery? (3 marks)

d) What are the prerequisites and contraindications for External Cephalic Version (ECV)? (4 marks)

e) She opts for ECV at 37 weeks. The procedure is unsuccessful. What is the recommended mode of delivery? (1 mark)

Model Answers:

(a) Frank (extended) breech: hips flexed, knees extended (most common, 65%); Complete (flexed) breech: hips and knees both flexed; Footling (incomplete) breech: one or both feet presenting; Knee presentation (rare)
(b) Idiopathic (most common), prematurity, polyhydramnios/oligohydramnios, uterine abnormality (septum, bicornuate), placenta praevia (low-lying), fetal abnormality (hydrocephalus, anencephaly), multiple pregnancy, cornual placenta, pelvic tumour
(c) ECV (37+ weeks, 50-60% success); elective CS (most women with persistent breech are offered CS - Term Breech Trial); planned vaginal breech birth (only in selected cases with skilled operator, flexed breech, normal-sized pelvis, EFW 2.5-3.5 kg, at consultant-led unit)
(d) Prerequisites for ECV: ≥36+0 weeks, singleton, non-cephalic presentation, intact membranes, reassuring CTG before and after, consent, IV access, facilities for emergency CS. Contraindications: placenta praevia/abruption, PPROM, multiple pregnancy, severe oligohydramnios, uterine scar with concern, fetal compromise, major fetal anomaly, Rh-negative (relative - give Anti-D)
(e) Elective caesarean section at 39 weeks (if no contraindication to expectant management)

MEQ 12 — Transverse/Oblique Lie & Face Presentation

A para 4 woman at 38 weeks presents in early labour. Abdominal examination shows a transverse lie. Membranes are intact.

a) What are the causes of unstable/transverse lie in a grand multipara? (3 marks)

b) What is the immediate danger if the membranes rupture in transverse lie? (1 mark)

c) What is "shoulder presentation" and what are its obstetric dangers? (3 marks)

d) Outline management of transverse lie in early labour with intact membranes. (3 marks)

Model Answers:

(a) Grande multiparity itself (lax uterine and abdominal walls), placenta praevia, pelvic tumour, uterine abnormality (septum), contracted pelvis, polyhydramnios, multiple pregnancy, fetal anomaly (anencephaly)
(b) Cord prolapse - arm or cord presents through cervix once membranes rupture with transverse lie; constitutes an obstetric emergency
(c) Shoulder presentation: fetus lies transversely with shoulder over the pelvic inlet; in labour, arm may prolapse. Dangers: cord prolapse, obstructed labour, uterine rupture (especially in multipara), maternal/fetal death if neglected
(d) Admit; CTG; IV access; if <37 weeks - attempt ECV; if ≥37 weeks in early labour with intact membranes - attempt ECV under USS guidance; if successful - ARM and oxytocin augmentation or allow spontaneous labour; if ECV fails or membranes rupture - immediate CS; prepare for general anaesthesia; neonatology standby

9. OBSTETRIC EMERGENCIES

MEQ 13 — Shoulder Dystocia

A primigravida delivers the fetal head at term, then progress halts. You notice the "turtle sign" (retraction of the head against the perineum). There is failure to restitute.

a) Define shoulder dystocia. What are the risk factors? (3 marks)

b) Describe the stepwise manoeuvres using the mnemonic HELPERR. (5 marks)

c) What is McRoberts' manoeuvre? Why is it the first-line manoeuvre? (2 marks)

d) What are the maternal and fetal complications? (3 marks)

Model Answers:

(a) Shoulder dystocia: failure of the fetal shoulders to deliver with standard obstetric manoeuvres after delivery of the fetal head, requiring additional manoeuvres. Risk factors: macrosomia (EFW >4 kg), previous shoulder dystocia (10% recurrence), GDM/DM, post-dates, obesity, prolonged 1st/2nd stage, instrumental delivery (especially forceps), short maternal stature
(b) H - Call for Help (obstetrician, senior midwife, anaesthetist, neonatologist, theatre team); E - Evaluate for Episiotomy (does not resolve bony dystocia but improves access); L - Legs (McRoberts); P - Pubic pressure (suprapubic, not fundal - Rubin I/II manoeuvre); E - Enter (internal manoeuvres - Rubin II, Woods screw, Reverse Woods/Barnum); R - Remove the posterior arm; R - Roll the patient (Gaskin all-fours position)
(c) McRoberts: hyperflexion of maternal thighs onto the abdomen by two assistants. Straightens the lumbosacral angle, rotates the symphysis pubis superiorly, flattens the lumbar lordosis - effectively increases relative AP diameter of the pelvis. Simplest, no equipment needed, success rate ~40-50% alone, >50% with added suprapubic pressure
(d) Maternal: 3rd/4th degree perineal tears, postpartum haemorrhage, uterine rupture, symphysis pubis diastasis. Fetal: brachial plexus injury (Erb's palsy - C5/C6, most common), Klumpke's palsy (C8/T1), clavicle fracture, humeral fracture, hypoxic-ischaemic encephalopathy, stillbirth

MEQ 14 — Eclampsia

A 25-year-old primigravida at 34 weeks is admitted following a generalised tonic-clonic seizure at home. She had a BP of 160/105 mmHg at her last antenatal visit and +++ proteinuria.

a) Define eclampsia. How does it differ from severe preeclampsia? (2 marks)

b) What is your immediate management of the acute seizure? (4 marks)

c) What is the drug of choice for preventing recurrent seizures and what is the regime? (3 marks)

d) When and how would you deliver this woman? (3 marks)

e) What postpartum complications of eclampsia should be monitored for? (2 marks)

Model Answers:

(a) Eclampsia: new-onset tonic-clonic seizures in a woman with preeclampsia (or occasionally without prior hypertension/proteinuria). Differs from severe preeclampsia by the occurrence of seizures; severe PET has BP ≥160/110 with end-organ damage (renal, hepatic, haematological, neurological) but no seizures
(b) Left lateral position (recovery); airway - suction, jaw thrust, nasopharyngeal airway; oxygen 15 L/min via non-rebreather mask; IV access; do NOT restrain; IV magnesium sulphate 4 g over 5 minutes (loading dose); monitor: pulse oximetry, BP, urine output; bloods: FBC, LFTs, U&E, coagulation, urate; CTG once stable; call senior obstetrician and anaesthetist immediately
(c) Magnesium sulphate (MgSO₄) - Collaborative Eclampsia Trial. Regime (Pritchard): loading dose 4 g IV over 5 min + 5 g IM each buttock; maintenance 5 g IM 4-hourly OR (Zuspan regime) IV infusion 1-2 g/hour for 24 hours after last fit. Monitor for toxicity: check patellar reflexes (absent = first sign, at ~7-10 mmol/L), respiratory rate >16/min, urine output >25 ml/hour. Antidote: Calcium gluconate 1 g IV (10 ml of 10% solution)
(d) Stabilise first (seizure control, BP control with labetalol IV/hydralazine/nifedipine); once stable - deliver regardless of gestation (eclampsia = indication for delivery); mode: aim for vaginal delivery if cervix favourable and fetal condition reassuring; otherwise CS (especially if early gestation, failed induction, fetal compromise). Steroids at 34 weeks before delivery
(e) Pulmonary oedema, HELLP syndrome, acute kidney injury (AKI), stroke/cerebral haemorrhage, DIC, retinal detachment, placental abruption, recurrent seizures (can occur postpartum - MgSO₄ for 24h post-delivery), maternal death

MEQ 15 — Cord Prolapse

A midwife calls you urgently. A para 1 woman at 38 weeks is in active labour (6 cm dilated). Artificial rupture of membranes was performed 2 minutes ago and the midwife can feel loops of cord in the vagina. CTG shows prolonged deceleration to 60 bpm.

a) Define cord prolapse and distinguish it from cord presentation. (2 marks)

b) List FOUR risk factors for cord prolapse. (2 marks)

c) Describe the emergency management steps. (5 marks)

d) What is the expected mode of delivery? (1 mark)

Model Answers:

(a) Cord prolapse: descent of umbilical cord through the cervix alongside or past the presenting part after membranes have ruptured. Cord presentation: cord lies in front of presenting part with membranes still intact (precursor to prolapse)
(b) Malpresentation (transverse, oblique, footling breech, face), unengaged head, preterm fetus, PROM with high presenting part, polyhydramnios, multiple pregnancy (especially second twin), iatrogenic (ARM with high presenting part), low-lying placenta, grand multiparity
(c) Call for help immediately (senior obstetrician, anaesthetist, theatre team, neonatologist); DO NOT remove hand from vagina - manually elevate presenting part off the cord to relieve compression; position: knee-chest (all-fours) position OR Trendelenburg; cord handling - keep cord warm and moist, do not compress or pull, wrap in warm wet towel if externalised; fill bladder with 500-750 ml saline (pushes presenting part up) if time allows/theatre not immediately available; oxygen 15 L/min to mother; Category 1 CS immediately (aim for delivery within 30 minutes); do not attempt vaginal delivery unless fully dilated, multiparous, and imminent - in that case urgent assisted delivery (forceps/vacuum)
(d) Emergency (Category 1) Caesarean Section - aim for delivery within 30 minutes of diagnosis (decision-to-delivery interval <30 min)

MEQ 16 — Uterine Rupture

A 32-year-old (G2P1, previous lower segment CS) is in active labour at 39 weeks. She is on oxytocin for augmentation. She suddenly develops severe tearing abdominal pain, fetal bradycardia (80 bpm), and her contractions stop. The CTG shows a prolonged deceleration.

a) What is the diagnosis? What clinical signs confirm it? (3 marks)

b) What are the risk factors for uterine rupture? (3 marks)

c) What is the immediate management? (3 marks)

d) At laparotomy, the rupture is found to be complete with the fetus partially extruded. What are the surgical options? (3 marks)

Model Answers:

(a) Uterine rupture. Signs: sudden severe abdominal pain (often described as tearing/ripping), cessation of contractions (paradoxical relief), fetal bradycardia/CTG abnormality, maternal tachycardia and hypotension, loss of fetal station on VE, haematuria (if bladder involvement), scar tenderness (preceding warning sign), recession of presenting part, vaginal bleeding (may be minimal with complete rupture - blood into abdomen)
(b) Previous CS scar (most common) - especially classical/inverted T; previous uterine surgery (myomectomy); grand multiparity; obstructed labour; malpresentation; oxytocin/prostaglandin use in scarred uterus; dehiscence progressing to rupture; uterine anomaly; trauma
(c) Call for help; 2 x large-bore IV; aggressive resuscitation (fluids, blood); O₂; Category 1 emergency laparotomy; blood group & cross-match (6 units), FBC, coagulation; Foley catheter; neonatology team; theatre prepared for possible hysterectomy; inform ICU
(d) Primary repair (if rupture edges clean, limited extension, haemostasis achievable, patient desires future fertility) - repair in 2 layers; Repair + tubal ligation (if family complete); Hysterectomy (if repair not possible - massive haemorrhage, bladder/vessel involvement, infection, multiple extensions); ligate internal iliac arteries/uterine arteries as adjunct to reduce bleeding

---> Note on uploaded PDF: The file "Eop MEQ_260612_112714.pdf" is a scanned image-based PDF with no text layer - standard extraction and OCR tools were unable to retrieve its content. The questions below are compiled independently from obstetric textbook knowledge (Creasy & Resnik's Maternal-Fetal Medicine, Clinical Anesthesiology, Barash) and follow the MEQ format standard to such exam papers.

Complete Obstetrics MEQ Question Bank

Here is a summary of all 16 questions prepared across your 9 topics:

#	Topic	Clinical Vignette Focus	Marks
1	GDM	Screening, OGTT diagnosis, risk factors	10
2	GDM	Complications, intrapartum glycaemia, postnatal follow-up	12
3	APH	Placenta praevia - diagnosis, classification, management	13
4	APH	Placental abruption - features, types, DIC	12
5	PPH	Primary PPH - 4T's, stepwise management, uterotonics	13
6	PPH	Secondary PPH - causes, risk factors, management	10
7	PROM	PROM at term - diagnosis, risks, chorioamnionitis	11
8	PPROM	Preterm PPROM - management, antibiotics, MgSO₄	13
9	Preterm Labour	Tocolytics, fFN, cervical length, corticosteroids	13
10	FGR	Doppler interpretation, causes, timing of delivery	14
11	Abnormal Presentation	Breech - types, ECV, mode of delivery	13
12	Abnormal Presentation	Transverse lie, cord prolapse risk, management	10
13	Obstetric Emergency	Shoulder dystocia - HELPERR, McRoberts, complications	13
14	Obstetric Emergency	Eclampsia - MgSO₄ regime, delivery, monitoring	14
15	Obstetric Emergency	Cord prolapse - emergency steps, category 1 CS	10
16	Obstetric Emergency	Uterine rupture - recognition, management, surgical options	12

Key recurring exam themes across all topics:

Always state a definition first, then risk factors, then management
Know the 4 T's of PPH, HELPERR for shoulder dystocia
Corticosteroids (betamethasone) and MgSO₄ appear in preterm, PPROM, preterm labour, FGR, and eclampsia
Doppler progression in FGR: normal → raised resistance → AEDF → REDF → absent/reversed DV "a" wave (each step = deterioration requiring action)
ORACLE I trial underpins erythromycin use in PPROM (and explains why co-amoxiclav is avoided - NEC risk)
Cord prolapse management: elevate the presenting part, knee-chest position, Category 1 CS within 30 min

Make a quick reference sheet of obstetric drugs, doses, and contraindications

Reading File

I'll query the medical library for drug data in parallel while building the reference sheet.

Finding Sources

Reading File

Finding Sources

Reading File

Excellent - I have solid textbook data. Now I'll generate the formatted PDF reference sheet.

Running Command

mkdir -p /tmp/workspace/obstetric-drugs && ls /tmp/workspace/obstetric-drugs/

Running Command

python3 << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm, mm from reportlab.platypus import (SimpleDocTemplate, Table, TableStyle, Paragraph, Spacer, HRFlowable, KeepTogether) from reportlab.lib.enums import TA_CENTER, TA_LEFT from reportlab.platypus import PageBreak OUTPUT = '/tmp/workspace/obstetric-drugs/Obstetric_Drug_Reference.pdf' doc = SimpleDocTemplate( OUTPUT, pagesize=A4, leftMargin=1.2*cm, rightMargin=1.2*cm, topMargin=1.5*cm, bottomMargin=1.5*cm, title="Obstetric Drug Quick Reference", author="Orris Medical" ) # ── Colours ────────────────────────────────────────────────────────────────── DARK_TEAL = colors.HexColor('#1a5276') MID_TEAL = colors.HexColor('#2e86c1') LIGHT_TEAL = colors.HexColor('#d6eaf8') HEADER_BG = colors.HexColor('#1a5276') HEADER_FG = colors.white ROW_ALT = colors.HexColor('#eaf4fb') ROW_WARN = colors.HexColor('#fdf2f8') ACCENT_PINK = colors.HexColor('#a93226') # ── Styles ──────────────────────────────────────────────────────────────────── base = getSampleStyleSheet() title_style = ParagraphStyle('Title', parent=base['Normal'], fontSize=18, textColor=colors.white, leading=22, alignment=TA_CENTER, fontName='Helvetica-Bold') subtitle_style = ParagraphStyle('Subtitle', parent=base['Normal'], fontSize=9, textColor=colors.HexColor('#d6eaf8'), leading=12, alignment=TA_CENTER, fontName='Helvetica') sec_style = ParagraphStyle('Section', parent=base['Normal'], fontSize=10, textColor=colors.white, leading=13, fontName='Helvetica-Bold', alignment=TA_LEFT) cell_style = ParagraphStyle('Cell', parent=base['Normal'], fontSize=7.2, leading=10, fontName='Helvetica', textColor=colors.black) cell_bold = ParagraphStyle('CellBold', parent=base['Normal'], fontSize=7.5, leading=10.5, fontName='Helvetica-Bold', textColor=DARK_TEAL) warn_style = ParagraphStyle('Warn', parent=base['Normal'], fontSize=7, leading=9.5, fontName='Helvetica', textColor=ACCENT_PINK) note_style = ParagraphStyle('Note', parent=base['Normal'], fontSize=6.8, leading=9, fontName='Helvetica-Oblique', textColor=colors.HexColor('#555555')) def P(txt, style=None): return Paragraph(txt if txt else '', style or cell_style) def Pb(txt): return Paragraph(txt if txt else '', cell_bold) def Pw(txt): return Paragraph(txt if txt else '', warn_style) # ══════════════════════════════════════════════════════════════════════════════ # DATA – (Drug, Route/Dose, Mechanism, Contraindications, Key Notes) # ══════════════════════════════════════════════════════════════════════════════ SECTIONS = [] # ───────────────────────────────────────────────── # 1. UTEROTONICS / PPH # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '1. UTEROTONICS (PPH Management)', 'cols': ['Drug', 'Route & Dose', 'Mechanism', 'Contraindications', 'Key Notes'], 'widths': [3.0*cm, 4.2*cm, 3.2*cm, 3.8*cm, 4.3*cm], 'rows': [ ['Oxytocin\n(1st line)', '10 IU slow IV bolus OR\n20–40 IU in 1 L NS\nat 200–500 mL/hr\n(IM 10 IU if no IV)', 'Oxytocin receptor\nagonist → uterine\ncontraction', 'Do NOT give rapid\nIV bolus (severe\nhypotension)', 'First-line; active\nmanagement of 3rd\nstage: 10 IU IM;\nshelf-life sensitive\nto heat'], ['Ergometrine /\nMethylergometrine', '0.2–0.5 mg IM/IV\nRepeat q 2–4 h\n(max 5 doses)', 'Ergot alkaloid →\ntonic uterine\ncontraction', 'HYPERTENSION,\npreeclampsia,\neclampsia, cardiac\ndisease, peripheral\nvascular disease', 'Onset: IM 2–5 min,\nIV 1 min; causes\nnausea/vomiting;\navoid IV route if\npossible'], ['Syntometrine', '1 ampoule IM\n(oxytocin 5 IU +\nergometrine 0.5 mg)', 'Combined oxytocin\n+ ergot effect', 'Same as ergometrine\n(hypertension,\npreeclampsia)', 'Used for active\n3rd-stage mgmt;\ndo NOT use in\nhypertension'], ['Carboprost\n(15-methyl PGF2α)', '0.25 mg IM q 15–90 min\nMax 2 mg (8 doses)', 'Prostaglandin F2α\nanalogue → strong\nuterine contraction', 'ASTHMA (bronchospasm),\nactive cardiac/\npulmonary/hepatic/\nrenal disease', 'Give antiemetic\n+antidiarrhoeal\nconcurrently; monitor\nO₂ sat; 3rd/4th line\nafter oxytocin/ergot'], ['Misoprostol\n(PGE1 analogue)', '800–1000 µg PR/SL/oral\n(single dose)', 'Prostaglandin E1\nanalogue → uterine\ncontraction', 'Known allergy;\ncaution in\nasthma (preferred\nover carboprost)', 'WHO-endorsed for\nresource-limited\nsettings; causes\npyrexia/shivering;\noral/SL for PPH\nprevention 600 µg'], ['Tranexamic Acid', '1 g IV over 10 min\n(repeat 1 g if\nbleeding >30 min\nor restarts)', 'Antifibrinolytic:\ninhibits plasminogen\nactivation', 'Active\nthromboembolic\ndisease; history\nof seizures\n(high doses)', 'WOMAN trial:\nreduces PPH\nmortality; give\nWITHIN 3 hours of\nbirth; NOT a\nuterotonic'], ] }) # ───────────────────────────────────────────────── # 2. ANTIHYPERTENSIVES IN PREGNANCY # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '2. ANTIHYPERTENSIVES IN PREGNANCY', 'cols': ['Drug', 'Route & Dose', 'Mechanism', 'Contraindications', 'Key Notes'], 'widths': [3.0*cm, 4.2*cm, 3.2*cm, 3.8*cm, 4.3*cm], 'rows': [ ['Labetalol\n(1st-line acute)', 'IV: 20 mg bolus; repeat\n20–80 mg q 10–30 min\n(max 300 mg)\nOral: 200–800 mg BD', 'α + β blocker;\ndecreases SVR;\npreserves\nplacental flow', 'Asthma/COPD,\nheart block,\nbradycardia,\nuncontrolled\nheart failure', 'ACOG 1st-line IV;\nonset 5 min;\nfetal bradycardia\npossible; do NOT\nuse in asthma'], ['Hydralazine\n(1st-line acute)', 'IV: 5 mg, then 5–10 mg\nq 20–40 min\n(max 20 mg)', 'Arteriolar\nvasodilator;\nincreases uterine\n& renal blood flow', 'SLE, coronary\nartery disease,\ndissecting\naortic aneurysm', 'Unpredictable\nduration; reflex\ntachycardia;\nneonatal\nthrombocytopenia\nreported'], ['Nifedipine\n(oral acute/chronic)', 'Acute: 10–20 mg oral;\nrepeat in 20 min if needed\nChronic: 30–90 mg SR\nonce daily', 'Calcium channel\nblocker → arterial\nvasodilation', 'Haemodynamic\ninstability,\nsevere aortic\nstenosis', 'ACOG endorsed;\nmay cause\nheadache; caution\nwith MgSO₄\n(enhanced\nhypotension);\nDO NOT use\nsublingual'], ['Methyldopa\n(chronic)', 'Oral: 250–500 mg TDS\n(max 3 g/day)', 'Central α₂ agonist\n→ reduces\nsympathetic tone', 'Depression,\nactive liver\ndisease,\nphaeochromocytoma', 'Safest for\nlong-term use;\nfetal safety\nwell established;\ncauses sedation,\ndry mouth'], ['Sodium Nitroprusside\n(refractory/ICU)', 'IV infusion: 0.3 µg/kg/min\n(max 10 µg/kg/min)', 'Direct NO donor\n→ arterial +\nvenous dilation', 'Avoid prolonged\nuse in pregnancy\n(cyanide toxicity\nto fetus)', 'Last resort; needs\narterial line;\ncyanide toxicity\nat high/prolonged\ndoses'], ['Atenolol /\nACE inhibitors /\nARBs', '— AVOID —', '—', 'CONTRAINDICATED\nin pregnancy', 'Atenolol → FGR;\nACEi/ARBs →\nneonatal AKI,\nskull hypoplasia,\noliguria, death'], ] }) # ───────────────────────────────────────────────── # 3. ANTICONVULSANTS (ECLAMPSIA) # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '3. ANTICONVULSANTS (Eclampsia / Preeclampsia)', 'cols': ['Drug', 'Route & Dose', 'Mechanism', 'Contraindications', 'Key Notes / Toxicity'], 'widths': [3.0*cm, 4.5*cm, 3.0*cm, 3.5*cm, 4.5*cm], 'rows': [ ['Magnesium Sulphate\n(DRUG OF CHOICE)', 'Pritchard: Load 4 g IV\nover 5 min + 5 g IM\neach buttock;\nMaintain 5 g IM q 4 h\n\nZuspan: Load 4 g IV\nover 20 min;\nMaintain 1–2 g/hr IV\nfor 24 h post-last fit', 'NMDA receptor\nantagonist;\ncerebral\nvasodilation;\nneuromuscular\nblockade', 'Myasthenia\ngravis; renal\nfailure (reduce\ndose); pre-existing\nheart block', 'TOXICITY (monitor):\n• Loss of patellar\n reflex: 7–10 mmol/L\n• Resp depression:\n >12 mmol/L\n• Cardiac arrest:\n >15 mmol/L\nANTIDOTE:\nCalcium gluconate\n1 g IV (10 mL of 10%)\nMonitor: reflexes,\nRR >16, UO >25 mL/h'], ['Diazepam\n(2nd line only)', 'IV: 10 mg over 2 min\n(repeat to max 30 mg)', 'GABA-A receptor\nagonist →\nsedation,\nanticonvulsant', 'Respiratory\ndepression;\navoid if\npossible in\npregnancy', 'Less effective\nthan MgSO₄;\nneonatal\nrespiratory\ndepression &\nhypothermia;\nuse only if\nMgSO₄ unavailable'], ['Phenytoin\n(rarely used)', 'IV: 15–18 mg/kg at\n<50 mg/min', 'Na+ channel\nblocker', 'Bradycardia,\nheart block,\nhypotension,\nneonatal\ncoagulopathy', 'MgSO₄ SUPERIOR\n(Collaborative\nEclampsia Trial);\nteratogenic\n(fetal hydantoin\nsyndrome)'], ] }) # ───────────────────────────────────────────────── # 4. TOCOLYTICS (Preterm Labour) # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '4. TOCOLYTICS (Preterm Labour – delay delivery to allow steroids / transfer)', 'cols': ['Drug', 'Route & Dose', 'Mechanism', 'Contraindications', 'Key Notes'], 'widths': [3.0*cm, 4.2*cm, 3.2*cm, 3.8*cm, 4.3*cm], 'rows': [ ['Atosiban\n(NICE preferred)', 'Bolus: 6.75 mg IV over\n1 min; then 18 mg/hr\nx 3 h; then 6 mg/hr\nup to 45 h', 'Oxytocin +\nvasopressin\nreceptor antagonist', '<24 weeks or\n≥34 weeks; PROM\nwith infection;\nfetal distress;\nAPH; lethal\nanomaly', 'Fewest maternal\nside effects;\ncostly; not\nassociated with\nneonatal harm;\n1st-line in UK'], ['Nifedipine\n(widely used)', 'Loading: 20 mg oral;\nthen 10–20 mg q\n4–6 h (or 30–60 mg\nSR once daily)', 'L-type Ca²⁺ channel\nblocker → uterine\nrelaxation', 'Hypotension,\nhaemodynamic\ninstability;\ncaution with\nMgSO₄', 'Cheap & effective;\nheadache common;\nFetal: case reports\nof placental\ninsufficiency;\nmay potentiate\nMgSO₄ hypotension'], ['Indometacin\n(NSAIDs)', '50–100 mg PR/oral\nloading, then 25 mg\nq 6 h (max 48 h)', 'COX inhibitor\n→ reduces\nprostaglandin\nsynthesis', '<24 weeks or\n>32 weeks (NEC,\npremature DA\nclosure); renal\nimpairment;\nulcer disease', 'Ductal constriction\n/closure if >32 wks;\noligohydramnios;\nNEC; limit to\n48 h & <32 wks;\ndo NOT repeat course'], ['Ritodrine /\nSalbutamol\n(β₂ agonists)', 'IV infusion:\nRitodrine 50–350 µg/min\nSalbutamol 10–45 µg/min', 'β₂ receptor\nagonist →\nuterine smooth\nmuscle relaxation', 'Cardiac disease,\nhypertension,\nthyrotoxicosis,\nDM (hyperglycaemia)', 'MANY side effects:\ntachycardia,\nhyperglycaemia,\nhypokalaemia,\npulmonary oedema;\nlargely replaced\nby atosiban/nifedipine'], ['Magnesium Sulphate\n(neuroprotection,\nnot tocolysis)', '4 g IV loading over\n20–30 min; then\n1 g/hr for ≤24 h\n(if <32 weeks)', 'Ca²⁺ antagonist;\ncerebral\nneuroprotection', 'Myasthenia\ngravis; renal\nfailure', 'Reduces cerebral\npalsy by ~30%\n(BEAM/MagNET);\nNOT a tocolytic;\ngive with steroids\nbefore preterm\nbirth <32 weeks'], ] }) # ───────────────────────────────────────────────── # 5. CORTICOSTEROIDS (Fetal Lung Maturity) # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '5. CORTICOSTEROIDS (Fetal Lung Maturity / Neuroprotection)', 'cols': ['Drug', 'Route & Dose', 'Indication', 'Contraindications', 'Key Notes'], 'widths': [3.0*cm, 4.2*cm, 3.2*cm, 3.8*cm, 4.3*cm], 'rows': [ ['Betamethasone\n(PREFERRED)', '12 mg IM x 2 doses,\n24 hours apart', 'Fetal lung\nmaturity:\n24–34+6 weeks;\nconsider up to\n36+6 wks', 'Active systemic\ninfection (relative);\nknown allergy', 'Reduces RDS, IVH,\nNEC, neonatal\nmortality; full\nbenefit after\n24 h; active for\n~7 days; single\nrescue course\nif >7 days since\nfirst & <34 wks'], ['Dexamethasone\n(alternative)', '6 mg IM q 12 h x\n4 doses (total 24 mg)', 'Same as\nbetamethasone\n(when unavailable)', 'Same as\nbetamethasone', 'Equivalent efficacy;\nsome prefer\nbetamethasone\n(benzyl alcohol\nfree); associated\nwith slightly\nhigher NEC\nrates in some studies'], ] }) # ───────────────────────────────────────────────── # 6. ANTIBIOTICS IN OBSTETRICS # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '6. ANTIBIOTICS IN OBSTETRICS', 'cols': ['Drug', 'Indication', 'Route & Dose', 'Contraindications', 'Key Notes'], 'widths': [3.2*cm, 3.2*cm, 3.8*cm, 3.5*cm, 4.8*cm], 'rows': [ ['Erythromycin', 'PPROM\n(<37 weeks)', '250 mg oral QDS\nx 10 days', 'Hepatic disease;\ncaution:\nQT prolongation', 'ORACLE I trial;\nDO NOT use\nco-amoxiclav\n(↑ NEC risk)'], ['Benzylpenicillin\n(Penicillin G)', 'GBS prophylaxis\nin labour', '3 g IV loading, then\n1.5 g IV q 4 h\nuntil delivery', 'Penicillin\nallergy → use\nclindamycin or\nvancomycin', 'Give ≥4 h before\ndelivery for\nfull neonatal\nprotection'], ['Ampicillin +\nGentamicin', 'Chorioamnionitis;\nendometritis', 'Ampicillin 2 g IV q 6 h\n+ Gentamicin\n1.5 mg/kg q 8 h\n(or 5 mg/kg q 24 h)', 'Gentamicin:\nnephrotoxicity,\nototoxicity;\nmonitor levels\nif prolonged', 'Add metronidazole\n500 mg IV q 8 h\nif post-CS\n(anaerobic cover);\ncheck gentamicin\ntroughs'], ['Metronidazole', 'Bacterial\nvaginosis;\nendometritis;\nretained products', '400–500 mg\noral/IV TDS\nx 5–7 days', '1st trimester\n(theoretical\nteratogenicity\n- controversial)', 'Avoid alcohol;\ndisulfiram-like\nreaction;\nwidely used after\n1st trimester'], ['Co-amoxiclav', 'Post-CS wound\ninfection; UTI\n(NOT PPROM)', '625 mg oral TDS or\n1.2 g IV TDS', 'Penicillin allergy;\nAVOID in PPROM\n(NEC risk)', 'ORACLE I: ↑ NEC\nwhen given for PPROM;\nstill safe\npost-CS for\nwound/endometritis'], ['Cefazolin', 'CS prophylaxis', '2 g IV single dose\n30–60 min pre-op\n(3 g if BMI >35)', 'Cephalosporin\nallergy; severe\npenicillin allergy\n(10% cross-react)', 'Reduces\nendomyometritis\n& wound infection\npost-CS;\nsingle dose\nsufficient'], ] }) # ───────────────────────────────────────────────── # 7. INDUCTION OF LABOUR # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '7. INDUCTION OF LABOUR', 'cols': ['Drug/Method', 'Route & Dose', 'Mechanism', 'Contraindications', 'Key Notes'], 'widths': [3.0*cm, 4.2*cm, 3.2*cm, 3.8*cm, 4.3*cm], 'rows': [ ['Dinoprostone\n(PGE2)', 'Vaginal gel: 1–2 mg\n(q 6 h, max 3 doses)\nPessary: 10 mg\n(controlled release\n24 h)', 'Prostaglandin E2\n→ cervical\nripening &\nuterine contraction', 'Previous uterine\nscar (relative);\nprior CS;\nfetal distress;\nalready in labour;\nGrand multipara', 'Continuous CTG\nfor 30 min after;\nremove pessary\nif hyperstimulation;\nRESCIND if\nuterine hyperstimulation'], ['Misoprostol\n(PGE1 - off-label)', 'Oral: 25 µg q 2 h\nor 50 µg q 4 h\nVaginal: 25–50 µg\nq 4–6 h', 'Prostaglandin E1\nanalogue', 'Previous uterine\nscar (AVOID in\nprior CS – risk\nof rupture);\nfetal distress', 'Cheap; effective;\nuterine\nhyperstimulation\nrisk; WHO-\nendorsed for IOL\nin resource-\nlimited settings'], ['Oxytocin\n(Syntocinon)', 'IV infusion: start\n1–2 mIU/min;\ntitrate q 30 min\n(max 20–40 mIU/min)\nper protocol', 'Oxytocin receptor\nagonist → uterine\ncontractions', 'Obstructed labour;\nfetal distress;\nprevious CS\n(use with caution);\ncephalopelvic\ndisproportion', 'Only after\ncervical ripening;\nnever bolus IV;\nmonitor CTG\ncontinuously;\nstop for\nhyperstimulation\nor FHR abnormality'], ['Mifepristone', 'Oral: 200–600 mg\n(24–48 h before\nprostaglandin)', 'Progesterone +\nglucocorticoid\nreceptor antagonist\n→ cervical ripening', 'Adrenal\ninsufficiency;\nlong-term\nsteroids;\ncoagulopathy', 'Used for\ntermination of\npregnancy &\nfetal death;\nprimes cervix\nbefore misoprostol;\nnot routine IOL'], ] }) # ───────────────────────────────────────────────── # 8. DIABETES IN PREGNANCY # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '8. DIABETES IN PREGNANCY (GDM & Pre-existing DM)', 'cols': ['Drug', 'Route & Dose', 'Mechanism', 'Contraindications', 'Key Notes'], 'widths': [3.0*cm, 4.2*cm, 3.2*cm, 3.8*cm, 4.3*cm], 'rows': [ ['Metformin', 'Oral: 500 mg OD/BD;\ntitrate to\n2500 mg/day', 'Biguanide;\ndecreases hepatic\ngluconeogenesis;\nimproves insulin\nsensitivity', 'eGFR <30;\nhepatic failure;\ncontrast media\nprocedures', 'May cross placenta;\nno teratogenicity;\nMiG trial:\nnon-inferior\nto insulin;\n2nd-line oral after\ndiet failure'], ['Glibenclamide\n(Glyburide)', 'Oral: 2.5–10 mg BD', 'Sulfonylurea;\nstimulates\npancreatic insulin\nsecretion', 'Renal failure;\nhepatic failure;\nG6PD deficiency', 'Crosses placenta;\n↑ neonatal\nhypoglycaemia;\nnot recommended\nas 1st-line in\nmost guidelines;\nprefer metformin\nor insulin'], ['Insulin\n(various types)', 'SC: Dose individualised;\nTarget:\nFasting <5.3 mmol/L;\n1-h post <7.8;\n2-h post <6.4 mmol/L', 'Exogenous insulin;\nbinds IR → glucose\nuptake', 'Hypoglycaemia\n(adjust dose);\nno absolute CI\nin pregnancy', 'Safe – does NOT\ncross placenta;\nIntrapartum:\nGIK infusion;\ntarget glucose\n4–7 mmol/L\nduring labour;\nstop post-delivery'], ] }) # ───────────────────────────────────────────────── # 9. RHESUS PROPHYLAXIS & HAEMATINICS # ───────────────────────────────────────────────── SECTIONS.append({ 'title': '9. RHESUS PROPHYLAXIS & HAEMATINICS', 'cols': ['Drug', 'Route & Dose', 'Indication', 'Contraindications', 'Key Notes'], 'widths': [3.0*cm, 4.2*cm, 3.2*cm, 3.8*cm, 4.3*cm], 'rows': [ ['Anti-D\n(Rh immunoglobulin)', 'RAADP:\n500 IU IM at 28 wks\n(+34 wks some centres)\nPost-sensitising event:\n250 IU IM (<20 wks)\n500 IU IM (≥20 wks)', 'Passive anti-D\nantibody →\nclears D+ fetal\nRBCs before\nmaternal\nsensitisation', 'Known sensitisation\n(alloimmunised);\nRhD-positive\nmother', 'Give within 72 h\nof sensitising event;\nKleihauer test if\nlarge FMH;\nadditional doses\nif FMH >4 mL fetal\nRBCs'], ['Ferrous Sulphate', '200 mg oral TDS\n(equiv. 65 mg\nelemental Fe)', 'Iron deficiency\nanaemia in\npregnancy;\npostpartum\nanaemia', 'Haemochromatosis;\nhaemolytic\nanaemia;\nthalassaemia\n(check first)', 'Take on empty\nstomach; ↑\nabsorption with\nvitamin C; causes\nconstipation,\nnausea; avoid\nwith antacids,\ntetracyclines'], ['IV Iron\n(Ferric carboxymaltose)', '500–1000 mg IV\nin 15 min\n(single dose,\nmax 1000 mg)', 'Iron replacement\n(when oral\nintolerant or\ninadequate\nresponse)', '1st trimester;\nknown iron\noverload; allergy\nto parenteral iron', 'Preferred for\nsevere IDA or\npoor oral tolerance;\ngive BEFORE\nCs rather than\npostpartum if\nHb <100 g/L;\nanaphylaxis risk'], ['Folic Acid', '400 µg oral daily\n(pre-conception\n+ 1st trimester)\n5 mg daily (high\nrisk: epilepsy, DM,\nobesity, prior NTD)', 'Required for\nDNA synthesis\n& neural tube\nclosure', 'Undiagnosed\nvitamin B12\ndeficiency\n(may mask\nanaemia)', 'Start ≥1 month\nbefore conception;\ncontinue to\n12 weeks; 5 mg\nfor epileptics\non enzyme\ninducers'], ] }) # ══════════════════════════════════════════════════════════════════════════════ # BUILD THE PDF # ══════════════════════════════════════════════════════════════════════════════ elements = [] # ── Title banner ────────────────────────────────────────────────────────────── title_data = [ [Paragraph('OBSTETRIC DRUG QUICK REFERENCE', title_style)], [Paragraph('Doses · Mechanisms · Contraindications · Key Notes | Based on ACOG, NICE, WHO & Creasy-Resnik MFM', subtitle_style)], ] title_tbl = Table(title_data, colWidths=[18.6*cm]) title_tbl.setStyle(TableStyle([ ('BACKGROUND', (0, 0), (-1, -1), DARK_TEAL), ('TOPPADDING', (0, 0), (-1, 0), 10), ('BOTTOMPADDING', (0, 1), (-1, -1), 8), ('LEFTPADDING', (0, 0), (-1, -1), 8), ('RIGHTPADDING', (0, 0), (-1, -1), 8), ('ROUNDEDCORNERS', [4, 4, 4, 4]), ])) elements.append(title_tbl) elements.append(Spacer(1, 0.4*cm)) WARN_DRUGS = {'AVOID', 'CONTRAINDICATED', 'DO NOT', 'AVOID in', 'TOXIC', 'ANTIDOTE'} def make_section_table(sec): col_widths = sec['widths'] # Header row header_row = [Paragraph(f'{c}', ParagraphStyle('H', parent=base['Normal'], fontSize=7.5, textColor=colors.white, fontName='Helvetica-Bold', leading=10)) for c in sec['cols']] rows_data = [header_row] for r in sec['rows']: row = [] for i, cell in enumerate(r): # Detect warning cells if any(w in str(cell) for w in WARN_DRUGS) and i in (3, 4): row.append(Pw(str(cell).replace('\n', ' '))) elif i == 0: row.append(Pb(str(cell).replace('\n', ' '))) else: row.append(P(str(cell).replace('\n', ' '))) rows_data.append(row) tbl = Table(rows_data, colWidths=col_widths, repeatRows=1) style_cmds = [ # Header ('BACKGROUND', (0, 0), (-1, 0), MID_TEAL), ('TEXTCOLOR', (0, 0), (-1, 0), colors.white), ('FONTNAME', (0, 0), (-1, 0), 'Helvetica-Bold'), ('FONTSIZE', (0, 0), (-1, 0), 7.5), ('BOTTOMPADDING', (0, 0), (-1, 0), 5), ('TOPPADDING', (0, 0), (-1, 0), 5), # Grid ('GRID', (0, 0), (-1, -1), 0.3, colors.HexColor('#b0c4de')), ('ROWBACKGROUNDS', (0, 1), (-1, -1), [colors.white, ROW_ALT]), ('VALIGN', (0, 0), (-1, -1), 'TOP'), ('TOPPADDING', (0, 1), (-1, -1), 4), ('BOTTOMPADDING', (0, 1), (-1, -1), 4), ('LEFTPADDING', (0, 0), (-1, -1), 4), ('RIGHTPADDING', (0, 0), (-1, -1), 4), ] tbl.setStyle(TableStyle(style_cmds)) return tbl for sec in SECTIONS: # Section header bar sec_banner = Table([[Paragraph(sec['title'], sec_style)]], colWidths=[18.6*cm]) sec_banner.setStyle(TableStyle([ ('BACKGROUND', (0, 0), (-1, -1), DARK_TEAL), ('TOPPADDING', (0, 0), (-1, -1), 4), ('BOTTOMPADDING', (0, 0), (-1, -1), 4), ('LEFTPADDING', (0, 0), (-1, -1), 6), ])) elements.append(KeepTogether([sec_banner, Spacer(1, 1*mm), make_section_table(sec)])) elements.append(Spacer(1, 0.35*cm)) # Footer note elements.append(HRFlowable(width='100%', thickness=0.5, color=MID_TEAL)) elements.append(Spacer(1, 1*mm)) footer_txt = ( 'Important: Always verify doses against current local formulary and guidelines. ' 'This sheet is a revision aid only and does not replace clinical judgment. ' 'Sources: Creasy & Resnik MFM (9780323828499), Roberts & Hedges Emergency Medicine, ' 'ACOG Practice Bulletins, NICE NG25/NG133/NG201, WHO Recommendations, WOMAN Trial, ORACLE I Trial.' ) elements.append(Paragraph(footer_txt, note_style)) doc.build(elements) print("PDF created:", OUTPUT) PYEOF

The PDF is ready. Here is the full reference sheet content, and your download link is below:

Obstetric Drug Reference

PDF Document · PDF

Obstetric Drug Quick Reference

1. Uterotonics (PPH Management)

Drug	Route & Dose	Mechanism	Contraindications	Key Notes
Oxytocin (1st line)	10 IU slow IV bolus OR 20-40 IU in 1 L NS at 200-500 mL/hr; IM 10 IU if no IV	Oxytocin receptor agonist	No rapid IV bolus (severe hypotension)	First-line; active 3rd-stage: 10 IU IM; heat-sensitive
Ergometrine / Methylergometrine	0.2-0.5 mg IM/IV; repeat q 2-4 h (max 5 doses)	Ergot alkaloid - tonic uterine contraction	HYPERTENSION, preeclampsia, eclampsia, cardiac disease, PVD	Onset IM 2-5 min; causes N&V; avoid IV route
Syntometrine	1 ampoule IM (oxytocin 5 IU + ergometrine 0.5 mg)	Combined oxytocin + ergot	Same as ergometrine	Active 3rd-stage only; avoid in any hypertension
Carboprost (15-methyl PGF2α)	0.25 mg IM q 15-90 min; max 2 mg (8 doses)	PGF2α analogue - strong uterine contraction	ASTHMA (bronchospasm), cardiac/pulmonary/hepatic/renal disease	Give antiemetic + antidiarrhoeal; 3rd/4th line agent
Misoprostol (PGE1)	800-1000 µg PR/SL/oral (single dose)	PGE1 analogue	Known allergy; caution asthma	WHO-endorsed in resource-limited settings; causes pyrexia/shivering
Tranexamic Acid	1 g IV over 10 min; repeat 1 g if bleeding >30 min	Antifibrinolytic - inhibits plasminogen activation	Active thromboembolic disease; seizure history	WOMAN trial: reduces PPH mortality; give within 3 hours of birth

2. Antihypertensives in Pregnancy

Drug	Dose	Contraindications	Key Notes
Labetalol (1st-line acute)	IV: 20 mg bolus; repeat 20-80 mg q 10-30 min (max 300 mg). Oral: 200-800 mg BD	Asthma/COPD, heart block, bradycardia, heart failure	ACOG 1st-line IV; fetal bradycardia possible
Hydralazine (1st-line acute)	IV: 5 mg, then 5-10 mg q 20-40 min (max 20 mg)	SLE, CAD, dissecting aneurysm	Unpredictable duration; reflex tachycardia
Nifedipine (oral acute/chronic)	Acute: 10-20 mg oral; repeat in 20 min. Chronic: 30-90 mg SR OD	Haemodynamic instability, severe aortic stenosis	Caution with MgSO₄ (hypotension); never sublingual
Methyldopa (chronic)	250-500 mg TDS (max 3 g/day)	Depression, active liver disease	Safest for long-term; fetal safety well established; causes sedation
Sodium Nitroprusside (ICU/refractory)	0.3 µg/kg/min IV (max 10 µg/kg/min)	Avoid prolonged use - fetal cyanide toxicity	Last resort; needs arterial line
ACEi / ARBs / Atenolol	— AVOID —	CONTRAINDICATED in pregnancy	ACEi/ARBs → neonatal AKI, skull hypoplasia, oliguria, death; atenolol → FGR

3. Anticonvulsants (Eclampsia)

Drug	Dose	Contraindications	Toxicity / Key Notes
Magnesium Sulphate (drug of choice)	Pritchard: Load 4 g IV over 5 min + 5 g IM each buttock; Maintain 5 g IM q 4 h. Zuspan: Load 4 g IV over 20 min; Maintain 1-2 g/hr IV x 24 h post-last fit	Myasthenia gravis; renal failure (reduce dose)	Toxicity: loss of patellar reflex (7-10 mmol/L), resp depression (>12), cardiac arrest (>15). Antidote: Calcium gluconate 1 g IV (10 mL of 10% solution). Monitor: reflexes, RR >16, UO >25 mL/h
Diazepam (2nd line only)	10 mg IV over 2 min (max 30 mg)	Respiratory depression	Less effective than MgSO₄; neonatal resp depression & hypothermia; use only if MgSO₄ unavailable
Phenytoin (rarely used)	15-18 mg/kg IV at <50 mg/min	Bradycardia, heart block, hypotension	MgSO₄ is superior (Collaborative Eclampsia Trial); teratogenic (fetal hydantoin syndrome)

4. Tocolytics (Preterm Labour)

Drug	Dose	Contraindications	Key Notes
Atosiban (NICE preferred)	Bolus 6.75 mg IV over 1 min; then 18 mg/hr x 3 h; then 6 mg/hr up to 45 h	<24 or ≥34 weeks; PROM with infection; fetal distress; APH; lethal anomaly	Fewest maternal side effects; 1st-line in UK; costly
Nifedipine (widely used)	Loading: 20 mg oral; then 10-20 mg q 4-6 h	Hypotension; caution with MgSO₄	Cheap and effective; headache common
Indometacin	50-100 mg PR loading; then 25 mg q 6 h (max 48 h)	>32 weeks (ductal closure), renal impairment, peptic ulcer	Ductal constriction/NEC/oligohydramnios if >32 weeks; limit to 48 h only
Salbutamol/Ritodrine (β₂ agonists)	IV infusion (titrated per protocol)	Cardiac disease, hypertension, thyrotoxicosis, DM	Many side effects (tachycardia, hyperglycaemia, pulmonary oedema); largely superseded
MgSO₄ (neuroprotection, NOT tocolysis)	4 g IV over 20-30 min; then 1 g/hr ≤24 h (if <32 weeks)	Myasthenia gravis; renal failure	Reduces cerebral palsy by ~30% (BEAM/MagNET trials)

5. Corticosteroids (Fetal Lung Maturity)

Drug	Dose	Indication	Key Notes
Betamethasone (preferred)	12 mg IM x 2 doses, 24 h apart	24-34+6 weeks (consider to 36+6)	Reduces RDS, IVH, NEC, neonatal mortality; full benefit after 24 h; single rescue course if >7 days since first course
Dexamethasone (alternative)	6 mg IM q 12 h x 4 doses (total 24 mg)	Same as betamethasone	Equivalent efficacy; use when betamethasone unavailable

6. Antibiotics in Obstetrics

Drug	Indication	Dose	Key Notes
Erythromycin	PPROM (<37 weeks)	250 mg oral QDS x 10 days	ORACLE I trial; DO NOT use co-amoxiclav (↑ NEC)
Benzylpenicillin	GBS prophylaxis in labour	3 g IV loading, then 1.5 g IV q 4 h	Give ≥4 h before delivery for full neonatal protection
Ampicillin + Gentamicin	Chorioamnionitis/endometritis	Ampicillin 2 g IV q 6 h + Gentamicin 5 mg/kg q 24 h	Add metronidazole 500 mg IV q 8 h for post-CS anaerobic cover
Cefazolin	CS prophylaxis	2 g IV single dose 30-60 min pre-op (3 g if BMI >35)	Single dose sufficient; reduces endometritis and wound infection
Co-amoxiclav	Post-CS wound/endometritis (NOT PPROM)	625 mg oral TDS or 1.2 g IV TDS	AVOID in PPROM - ORACLE I showed ↑ NEC

7. Induction of Labour

Drug	Dose	Contraindications	Key Notes
Dinoprostone (PGE2)	Vaginal gel 1-2 mg q 6 h (max 3); Pessary 10 mg controlled-release x 24 h	Previous CS scar (relative); fetal distress	Remove pessary for hyperstimulation; CTG 30 min after each dose
Misoprostol (PGE1 - off-label)	Oral 25 µg q 2 h or vaginal 25-50 µg q 4-6 h	AVOID with prior CS (uterine rupture risk)	WHO-endorsed for resource-limited settings; ↑ hyperstimulation risk
Oxytocin (Syntocinon)	Start 1-2 mIU/min IV; titrate q 30 min (max 20-40 mIU/min)	Obstructed labour; fetal distress; CPD	Only after cervical ripening; never bolus IV; continuous CTG required

8. Diabetes in Pregnancy

Drug	Dose	Contraindications	Key Notes
Metformin	500 mg OD, titrate to 2500 mg/day	eGFR <30, hepatic failure	MiG trial: non-inferior to insulin; no teratogenicity; 2nd-line oral after diet failure
Insulin	SC, individualised; Target: fasting <5.3, 1-h post <7.8, 2-h post <6.4 mmol/L	Hypoglycaemia (adjust dose)	Does NOT cross placenta; intrapartum GIK infusion; target 4-7 mmol/L in labour

9. Rhesus Prophylaxis & Haematinics

Drug	Dose	Indication	Key Notes
Anti-D (Rh immunoglobulin)	RAADP: 500 IU IM at 28 weeks. Post-sensitising event: 250 IU (<20 wks) / 500 IU (≥20 wks) IM	Rh-negative mother - prevent alloimmunisation	Give within 72 h of sensitising event; Kleihauer if large FMH
Ferrous Sulphate	200 mg TDS oral (65 mg elemental Fe)	IDA in pregnancy	Take with Vitamin C; avoid with antacids/tetracyclines; causes constipation
IV Ferric Carboxymaltose	500-1000 mg IV over 15 min (single dose)	IDA - oral intolerant or inadequate response	Preferred for severe IDA; not in 1st trimester; rare anaphylaxis
Folic Acid	400 µg OD (pre-conception + 1st trimester). 5 mg OD for high risk (epilepsy, DM, prior NTD, obesity)	Neural tube defect prevention	Start ≥1 month before conception; continue to 12 weeks

Critical memory hooks: MgSO₄ antidote = calcium gluconate 1 g IV | Carboprost avoided in asthma | Ergometrine avoided in hypertension | Co-amoxiclav avoided in PPROM (NEC) | ACEi/ARBs always contraindicated in pregnancy | Tranexamic acid within 3 hours of delivery | Indometacin avoid >32 weeks (ductal closure)

Generate few questions from the file above with the topics given

The user wants questions generated from the drug reference sheet created earlier, styled like the MEQ format, covering the topics in that file (uterotonics, antihypertensives, anticonvulsants, tocolytics, corticosteroids, antibiotics, IOL drugs, diabetes drugs, Rh prophylaxis & haematinics).

Let me generate these directly from the reference sheet content - no need for tool calls since all the data is in context.

MEQ Questions from the Obstetric Drug Reference Sheet

SECTION 1 - UTEROTONICS (PPH)

MEQ 1

A 28-year-old woman (G3P2) delivers normally at term. Active management of the third stage is given. At 20 minutes post-delivery she has heavy ongoing bleeding and the uterus feels boggy. Blood loss is estimated at 900 mL and increasing.

a) What is the FIRST-LINE uterotonic agent, its dose, and the single most important instruction about its administration route? (3 marks)

Answer: Oxytocin (Syntocinon). Dose: 20-40 IU in 1 L normal saline infused at 200-500 mL/hr IV; OR 10 IU IM if no IV access. Never give as an IV bolus - causes severe hypotension and cardiovascular collapse.

b) Bleeding continues despite oxytocin. You consider carboprost. Name TWO absolute contraindications and explain the physiological reason for the most dangerous one. (3 marks)

Answer: (i) Asthma - carboprost (15-methyl PGF2α) causes potent bronchospasm via prostaglandin F2α-mediated bronchoconstriction, which can be life-threatening in an asthmatic. (ii) Active cardiac / pulmonary / hepatic / renal disease. One mark for each contraindication + one mark for mechanism of bronchospasm.

c) You administer tranexamic acid. What is the dose, route, and the CRITICAL time window within which it must be given? What trial supports its use? (3 marks)

Answer: 1 g IV over 10 min; repeat 1 g if bleeding persists >30 min or restarts. Must be given within 3 hours of delivery. Supported by the WOMAN trial (World Maternal Antifibrinolytic Trial).

d) The patient has known hypertension. Which uterotonic agent is CONTRAINDICATED and why? (2 marks)

Answer: Ergometrine / Methylergometrine / Syntometrine are contraindicated. They cause intense vasoconstriction (ergot alkaloid effect), leading to dangerous hypertensive crisis, stroke, or MI in patients with pre-existing hypertension or preeclampsia.

SECTION 2 - ANTIHYPERTENSIVES IN PREGNANCY

MEQ 2

A 31-year-old primigravida at 36 weeks has a sustained BP of 168/112 mmHg on two readings 15 minutes apart. She has +++ proteinuria. She is alert with no headache.

a) Name the TWO first-line IV agents for acute severe hypertension in pregnancy. Give a dose for each. (4 marks)

Answer:

Labetalol IV: 20 mg bolus, repeat 20-80 mg every 10-30 min (max 300 mg)

Hydralazine IV: 5 mg, then 5-10 mg every 20-40 min (max 20 mg total) (2 marks each for drug + dose)

b) The on-call doctor suggests using oral atenolol as it is easily available. Why is this inappropriate? (2 marks)

Answer: Atenolol is contraindicated in pregnancy - associated with fetal growth restriction (FGR), neonatal bradycardia, and hypoglycaemia. It crosses the placenta and causes fetal beta-blockade.

c) The woman is known to have asthma. Which first-line antihypertensive must be AVOIDED and why? (2 marks)

Answer: Labetalol must be avoided. It has β-blocking activity and can precipitate severe bronchospasm in patients with asthma or COPD.

d) She is stabilised and needs long-term oral antihypertensive treatment for the remainder of her pregnancy. Name the SAFEST oral agent for chronic use in pregnancy and its dose. (2 marks)

Answer: Methyldopa 250-500 mg TDS (max 3 g/day). It has the longest safety record in pregnancy with no teratogenicity demonstrated.

SECTION 3 - ANTICONVULSANTS (ECLAMPSIA)

MEQ 3

A 24-year-old primigravida at 34 weeks is brought in following a tonic-clonic seizure. BP is 170/115 mmHg. She has no prior history of epilepsy.

a) What is the drug of choice for seizure control and prevention of recurrence in eclampsia? Give the FULL Pritchard regime. (4 marks)

Answer: Magnesium sulphate (MgSO₄).

Loading: 4 g IV over 5 minutes + 5 g IM into each buttock (10 g IM total)

Maintenance: 5 g IM every 4 hours for 24 hours after the last seizure (1 mark each for IV loading dose, IM loading, maintenance dose, duration)

b) List THREE parameters you must monitor during MgSO₄ therapy, and state the minimum acceptable value for each. (3 marks)

Answer:

Patellar reflexes - must be present (absent reflex = toxic level approaching)

Respiratory rate - must be >16 breaths/min

Urine output - must be >25 mL/hour

c) The patient develops absent patellar reflexes and her respiratory rate drops to 10/min. What is the antidote and exact dose? (2 marks)

Answer: Calcium gluconate 1 g IV (given as 10 mL of 10% solution) - administered slowly IV; reverses magnesium toxicity within minutes.

d) At what approximate serum magnesium level does each of the following occur: (i) loss of patellar reflex (ii) respiratory depression (iii) cardiac arrest? (3 marks)

Answer: (i) 7-10 mmol/L (ii) >12 mmol/L (iii) >15 mmol/L

SECTION 4 - TOCOLYTICS

MEQ 4

A 29-year-old woman (G1P0) presents at 30 weeks with painful regular contractions every 4 minutes, cervical dilation of 2 cm, and intact membranes. CTG is reactive, temperature normal.

a) Name the NICE-preferred tocolytic agent. Give the full dosing regime. (3 marks)

Answer: Atosiban (oxytocin/vasopressin receptor antagonist).

Bolus: 6.75 mg IV over 1 minute

Then: 18 mg/hr for 3 hours

Then: 6 mg/hr for up to 45 hours

b) Name FOUR absolute contraindications to tocolysis (applicable to any agent). (2 marks)

Answer: Any four from: gestation <24 weeks or ≥34 weeks; PPROM with signs of infection/chorioamnionitis; fetal distress/compromise; significant antepartum haemorrhage; lethal fetal anomaly; severe preeclampsia (with agents like nifedipine - relative); placenta praevia with active bleeding.

c) Indometacin is considered at 30 weeks. State TWO serious fetal complications if it is continued beyond 32 weeks, and what is the maximum recommended duration of use? (3 marks)

Answer: (i) Premature closure / constriction of the ductus arteriosus (ductal constriction leading to fetal cardiac failure); (ii) Oligohydramnios (due to reduced fetal renal prostaglandin-dependent blood flow); (iii) Necrotising enterocolitis (NEC). Maximum duration: 48 hours only; do not use beyond 32 weeks.

d) Magnesium sulphate is commenced alongside tocolysis. What is its specific purpose at 30 weeks, what is the loading dose, and which landmark trials support its use? (3 marks)

Answer: Neuroprotection - reduces the incidence of cerebral palsy and intraventricular haemorrhage in preterm neonates. Loading dose: 4 g IV over 20-30 min, then 1 g/hr for up to 24 hours. Supported by the BEAM trial (Beneficial Effects of Antenatal Magnesium) and MagNET trial - reduces cerebral palsy by approximately 30%.

SECTION 5 - CORTICOSTEROIDS

MEQ 5

A woman at 29 weeks is in threatened preterm labour. Her last course of antenatal corticosteroids was 3 weeks ago.

a) Name the preferred corticosteroid, dose, and schedule for fetal lung maturity. (2 marks)

Answer: Betamethasone 12 mg IM, two doses 24 hours apart.

b) What neonatal benefits do antenatal corticosteroids provide? List FOUR. (2 marks)

Answer: Reduces: (i) Respiratory distress syndrome (RDS); (ii) Intraventricular haemorrhage (IVH); (iii) Necrotising enterocolitis (NEC); (iv) Neonatal mortality; (v) Need for surfactant therapy - any 4.

c) Is a rescue (repeat) course of corticosteroids indicated in this woman? State the criteria. (2 marks)

Answer: Yes - a single rescue course is appropriate if: (i) the previous course was given >7 days ago, AND (ii) gestation is <34 weeks, AND (iii) preterm delivery is still likely imminent.

d) If betamethasone is unavailable, what is the alternative and its regime? (2 marks)

Answer: Dexamethasone 6 mg IM every 12 hours x 4 doses (total 24 mg over 48 hours). Equivalent efficacy to betamethasone.

SECTION 6 - ANTIBIOTICS IN OBSTETRICS

MEQ 6

A 27-year-old at 30 weeks presents with confirmed PPROM. She is afebrile, CTG is reactive.

a) Which antibiotic is recommended for PPROM and what is the dose and duration? Name the trial that established this. (3 marks)

Answer: Erythromycin 250 mg oral QDS (four times daily) for 10 days. Established by the ORACLE I trial (Kenyon et al., Lancet 2001).

b) A colleague suggests using co-amoxiclav as it provides broader coverage. Why is this specifically contraindicated in PPROM? (2 marks)

Answer: The ORACLE I trial demonstrated a statistically significant increase in neonatal necrotising enterocolitis (NEC) when co-amoxiclav was given for PPROM. Despite better antimicrobial coverage, the gut harm to the neonate outweighs any benefit.

c) This woman goes into labour at 32 weeks. Her GBS status is unknown. What antibiotic do you give intrapartum, what is the dose, and why must it be given early? (3 marks)

Answer: Benzylpenicillin (Penicillin G): loading dose 3 g IV, then 1.5 g IV every 4 hours until delivery. Must be given at least 4 hours before delivery to achieve adequate neonatal tissue levels and provide full protection against early-onset GBS neonatal sepsis.

d) She delivers by emergency CS. What prophylactic antibiotic is given and when? (2 marks)

Answer: Cefazolin 2 g IV single dose (3 g if BMI >35), administered 30-60 minutes before skin incision. Reduces post-CS endometritis and wound infection.

SECTION 7 - INDUCTION OF LABOUR

MEQ 7

A 38-year-old primigravida at 41+3 weeks has an unfavourable cervix (Bishop score 3). Induction of labour is planned.

a) What agent is used for cervical ripening? Name TWO available formulations and their doses. (3 marks)

Answer: Dinoprostone (PGE2):

Vaginal gel: 1-2 mg, repeated every 6 hours (max 3 doses)

Controlled-release pessary: 10 mg, single insertion for up to 24 hours

b) What action must be taken if uterine hyperstimulation occurs after dinoprostone insertion? (2 marks)

Answer: Remove the pessary/gel immediately (insert tocolytic if needed - e.g., terbutaline 0.25 mg SC); place in left lateral position; give oxygen; perform continuous CTG monitoring; call for senior help.

c) Her membranes are ruptured and the cervix is 4 cm dilated 18 hours later. Contractions are inadequate. Oxytocin infusion is commenced. Name TWO contraindications to oxytocin and state the ONE instruction about its route that is non-negotiable. (3 marks)

Answer: Contraindications: (i) Obstructed labour / cephalopelvic disproportion; (ii) Fetal distress on CTG; (iii) Previous CS with concern (relative); (iv) Grand multiparity (relative). Non-negotiable: NEVER administer as an IV bolus (causes severe hypotension and potential cardiovascular collapse). Always give as a dilute infusion.

d) Why is misoprostol for IOL contraindicated in a woman with a previous caesarean section? (2 marks)

Answer: Misoprostol (PGE1) causes intense uterine contractions and markedly increases the risk of uterine rupture along the previous CS scar. The risk is significantly higher than with dinoprostone (PGE2) and is considered unacceptable in most guidelines.

SECTION 8 - DIABETES IN PREGNANCY (GDM)

MEQ 8

A 34-year-old woman with GDM fails dietary management. Fasting glucose is 6.2 mmol/L and 2-hour postprandial glucose is 8.9 mmol/L on three consecutive days.

a) What are the target blood glucose levels in GDM? (2 marks)

Answer: Fasting: <5.3 mmol/L; 1-hour postprandial: <7.8 mmol/L; 2-hour postprandial: <6.4 mmol/L

b) Metformin is started. How does it work and what is its starting dose? (2 marks)

Answer: Metformin is a biguanide that primarily decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Starting dose: 500 mg once or twice daily, titrated up to 2500 mg/day as tolerated.

c) Name ONE advantage and ONE disadvantage of using metformin over insulin in GDM. (2 marks)

Answer: Advantage: Oral, no injection, patient acceptability, lower cost, no hypoglycaemia as monotherapy. Disadvantage: Crosses the placenta (long-term fetal implications unknown); GI side effects (nausea, diarrhoea); may not achieve adequate control in severe GDM requiring insulin add-on.

d) At 38 weeks she is admitted in labour. She takes Mixtard 30 insulin. How is glycaemic control managed during labour and what is the target? (3 marks)

Answer: Start glucose-insulin-potassium (GIK) infusion or variable-rate insulin infusion (VRIII); stop long-acting SC insulin; monitor capillary blood glucose every 1 hour; target glucose 4-7 mmol/L throughout labour. Adjust infusion rate accordingly to avoid neonatal hypoglycaemia.

SECTION 9 - RHESUS PROPHYLAXIS & HAEMATINICS

MEQ 9

A 26-year-old (G2P1) is Rh D-negative. She is 11 weeks pregnant and undergoes amniocentesis for karyotyping. She has no antibodies on current blood group screen.

a) Why does this woman require Anti-D immunoglobulin? What dose and route should be given? (3 marks)

Answer: Amniocentesis is a sensitising event - it can cause feto-maternal haemorrhage, exposing the Rh-negative mother to D-positive fetal red cells, triggering alloimmunisation. At ≥20 weeks: 500 IU IM. At <20 weeks: 250 IU IM. Must be given within 72 hours of the sensitising event.

b) She declines RAADP (routine antenatal anti-D prophylaxis) at 28 weeks. Explain what RAADP is and why it is recommended. (2 marks)

Answer: RAADP = Routine Antenatal Anti-D Prophylaxis given to ALL Rh-negative non-sensitised women regardless of the fetal Rh status (which is unknown antenatally). Given at 28 weeks (500 IU IM), and sometimes again at 34 weeks. Rationale: 50% of Rh-negative women carrying an Rh-positive fetus have small spontaneous feto-maternal bleeds in the 3rd trimester; RAADP prevents sensitisation before sensitisation occurs.

c) She is found to have haemoglobin of 9.2 g/dL at 30 weeks with a low MCV and low ferritin. She cannot tolerate oral iron due to severe nausea. What IV iron preparation can be used, and what are its contraindications? (3 marks)

Answer: Ferric carboxymaltose IV: 500-1000 mg as a single IV infusion over 15 minutes. Contraindications: First trimester (teratogenic risk unknown); known iron overload (haemochromatosis, haemolytic anaemia, thalassaemia); known allergy to parenteral iron. Risk of anaphylaxis - observe for 30 minutes post-infusion.

d) A colleague prescribes ferrous sulphate to another patient who is also on antacids for heartburn. What interaction should be warned about, and how should the patient be advised to take oral iron? (2 marks)

Answer: Antacids reduce absorption of oral iron (alkaline environment chelates ferrous ions). Patient should take ferrous sulphate on an empty stomach or between meals, at least 2 hours apart from antacids. Absorption is further enhanced by taking with Vitamin C (ascorbic acid).

Quick Drug ID Questions (SAQ Format - 1 mark each)

Which tocolytic is avoided in asthma? - Carboprost (bronchospasm)
Which antibiotic for PPROM causes NEC when used? - Co-amoxiclav
Antidote for MgSO₄ toxicity? - Calcium gluconate 1 g IV
Which antihypertensive is safe as chronic oral therapy but contraindicated in depression? - Methyldopa
What is the maximum total IV dose of labetalol in acute severe hypertension? - 300 mg
Which prostaglandin analogue for IOL is contraindicated with a uterine scar? - Misoprostol
Folic acid dose for a woman on valproate planning pregnancy? - 5 mg daily
Which drug in pregnancy causes neonatal AKI, skull hypoplasia, and oliguria? - ACE inhibitors / ARBs
Time limit for tranexamic acid in PPH? - Within 3 hours of delivery
Which trial showed MgSO₄ reduces cerebral palsy by ~30%? - BEAM / MagNET trials

This is a shared conversation. Sign in to Orris to start your own chat.